Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(benztropine)
997 results
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Parkinson Disease Agents [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Parkinson disease is a progressive neurological condition characterized by slowness and paucity of movement (bradykinesia), muscle rigidity, resting tremors, and disordered posture. The onset is typically in the 6th or 7th decade of life with slow progression to akinesia, severe tremors, physical disability and death within 10 to 25 years of initial symptoms. Parkinson disease is common and affec…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Benztropine [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Benztropine is an anticholinergic agent used predominantly in the symptomatic therapy of Parkinson disease and movement disorders. Benztropine has not been associated with serum enzyme elevations during treatment and has not been linked to cases of clinically apparent acute liver injury.
  • Acute dystonic reaction induced by a single dose of clebopride: A case report. [Case Reports]
    Medicine (Baltimore). 2019 May; 98(22):e15826.Seo YW, Ko SH, … Kim GM
  • CONCLUSIONS: Although it is uncommon to experience extrapyramidal symptoms by clebopride, its chemical closeness to metoclopramide may induce such symptoms under certain clinical situations. Therefore, physicians should take in consideration of this effect and dwell in caution upon prescribing the drug.
  • Psychotropics in Your Medicine Cabinet: A Case Study of Dimenhydrinate Use. [Journal Article]
    J Addict Med. 2019 Sep/Oct; 13(5):412-414.Wen X, Di Paola F, Chopra N
  • : Reporting of intoxication and withdrawal from aberrant use of over-the-counter medication has been sparse and inconsistent in literature. Attributed to their anticholinergic properties, medications such as dimenhydrinate (Gravol) taken in supratherapeutic doses have been associated with euphoria, anxiolysis, and hallucinations. We present a case of a woman in her forties, with a psychiatric his…
  • Lithium: contributor to movement disorder sensitivity after anoxic brain injury? [Case Reports]
    SAGE Open Med Case Rep. 2019; 7:2050313X18823101.Pikard JL, Oliver D, … Groll D
  • Although lithium-induced dystonia has been well documented in the literature, conflicting evidence discusses whether a patient may be susceptible to adverse effects from the drug after an anoxic brain injury. More recent literature discusses that lithium may, in fact, be neuroprotective. This case report presents a 35-year-old male who, after an anoxic brain injury after a suicide attempt, develo…
  • Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth. [Journal Article]
    Acta Neuropathol Commun. 2019 01 18; 7(1):9.Cerles O, Gonçalves TC, … Batteux F
  • The endogenous cholinergic system plays a key role in neuronal cells, by suppressing neurite outgrowth and myelination and, in some cancer cells, favoring tumor growth. Platinum compounds are widely used as part of first line conventional cancer chemotherapy; their efficacy is however limited by peripheral neuropathy as a major side-effect. In a multiple sclerosis mouse model, benztropine, that a…
  • Tuftsin Combines With Remyelinating Therapy and Improves Outcomes in Models of CNS Demyelinating Disease. [Journal Article]
    Front Immunol. 2018; 9:2784.Thompson KK, Nissen JC, … Tsirka SE
  • Though promoting remyelination in multiple sclerosis (MS) has emerged as a promising therapeutic strategy, it does not address inflammatory signals that continue to induce neuronal damage and inhibit effectiveness of repair mechanisms. Our lab has previously characterized the immunomodulatory tetrapeptide, tuftsin, which induces an anti-inflammatory shift in microglia and macrophages. This target…
  • Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial. [Randomized Controlled Trial]
    JAMA Intern Med. 2018 11 01; 178(11):1474-1481.Urquhart DM, Wluka AE, … Cicuttini FM
  • CONCLUSIONS: This trial suggests that amitriptyline may be an effective treatment for chronic low back pain. There were no significant improvements in outcomes at 6 months, but there was a reduction in disability at 3 months, an improvement in pain intensity that was nonsignificant at 6 months, and minimal adverse events reported with a low-dose, modest sample size and active comparator. Although large-scale clinical trials that include dose escalation are needed, it may be worth considering low-dose amitriptyline if the only alternative is an opioid.
  • Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter. [Journal Article]
    Neurochem Int. 2019 02; 123:34-45.Tomlinson MJ, Krout D, … Vaughan RA
  • The dopamine transporter (DAT) is a neuronal membrane protein that is responsible for reuptake of dopamine (DA) from the synapse and functions as a major determinant in control of DA neurotransmission. Cocaine and many psychostimulant drugs bind to DAT and block reuptake, inducing DA overflow that forms the neurochemical basis for euphoria and addiction. Paradoxically, however, some ligands such …
  • Drugs and Lactation Database (LactMed): Benztropine [BOOK]
    . National Library of Medicine (US): Bethesda (MD)BOOK
  • No information is available on the use of benztropine during breastfeeding. Long-term use of benztropine might reduce milk production or milk letdown, but a single dose is not likely to interfere with breastfeeding. During long-term use, observe for signs of decreased lactation (e.g., insatiety, poor weight gain).
  • Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects. [Journal Article]
    J Pharmacol Exp Ther. 2018 09; 366(3):527-540.Hong WC, Wasko MJ, … Katz JL
  • Atypical dopamine transporter (DAT) inhibitors, despite high DAT affinity, do not produce the psychomotor stimulant and abuse profile of standard DAT inhibitors such as cocaine. Proposed contributing features for those differences include off-target actions, slow onsets of action, and ligand bias regarding DAT conformation. Several 3α-(4',4''-difluoro-diphenylmethoxy)tropanes were examined, inclu…
  • Targeting the FKBP51/GR/Hsp90 Complex to Identify Functionally Relevant Treatments for Depression and PTSD. [Journal Article]
    ACS Chem Biol. 2018 08 17; 13(8):2288-2299.Sabbagh JJ, Cordova RA, … Blair LJ
  • Genetic and epigenetic alterations in FK506-binding protein 5 (FKBP5) have been associated with increased risk for psychiatric disorders, including post-traumatic stress disorder (PTSD). Some of these common variants can increase the expression of FKBP5, the gene that encodes FKBP51. Excess FKBP51 promotes hypothalamic-pituitary-adrenal (HPA) axis dysregulation through altered glucocorticoid rece…
  • Anticholinergic medication for antipsychotic-induced tardive dyskinesia. [Review]
    Cochrane Database Syst Rev. 2018 01 17; 1:CD000204.Bergman H, Soares-Weiser K
  • CONCLUSIONS: Based on currently available evidence, no confident statement can be made about the effectiveness of anticholinergics to treat people with antipsychotic-induced tardive dyskinesia. The same applies for the withdrawal of such medications. Whether the withdrawal of anticholinergics may benefit people with antipsychotic-induced TD should be evaluated in a parallel-group, placebo-controlled randomised trial, with adequate sample size and at least 6 weeks of follow-up.
New Search Next